Takehiro Tozuka

Dr. Takehiro Tozuka

Nippon Medical School, Tokyo, Japan
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TTTakehiro Tozuka
Takehiro Tozuka
SKSatoru Kitazono
Satoru Kitazono
HSHiroaki Sakamoto
Hiroaki Sakamoto
HYHiroshi Yoshida
Hiroshi Yoshida
YAYoshiaki Amino
Yoshiaki Amino
MNMakoto Nishio
Makoto Nishio
Background: Dissociated responses (DR) are phenomena in which some tumors shrink, whereas others progress during treatment of patients with cancer. The purpose of the present study was to evaluate the frequency and prognosis of DR in non-small cell lung cancer (NSCLC) patients treated with anti-programmed cell death-1/ligand 1 (anti-PD-1/L1) inhibitors. Methods: This retrospective study included NSCLC patients who received anti-PD-1/L1 inhibitor as second- or later-line treatment. We excluded patients without radiological evaluation. In patients who showed progressive disease (PD) according to the RECIST 1.1 at the initial CT evaluation, we evaluated all measurable lesions in each organ to identify DR independently of RECIST 1.1. We defined DR as a disease with some shrinking lesions as well as growing or emerging new lesions. Cases not classified as DR were defined as ‘true PD’. Overall survival was compared between patients with DR and those with true PD using Cox proportional hazards models. Results: The present study included 62 NSCLC patients aged 27–82 years (median: 65 years). DR and true PD were observed in 11 and 51 patients, respectively. The frequency of DR in NSCLC patients who showed PD to anti-PD-1/L1 was 17.7%. Median overall survival was significantly longer in patients with DR versus true PD (14.0 vs. 6.6 months, respectively; hazard ratio for death: 0.40; 95% confidence interval: 0.17–0.94). Conclusions: Patients with DR exhibited a relatively favorable prognosis.

24 March 2024 in Lung Cancer
Verified
Journal Article
Closed access
TTTakehiro Tozuka
Takehiro Tozuka
RNRintaro Noro
Rintaro Noro
HMHideaki Mizutani
Hideaki Mizutani
FKFutoshi Kurimoto
Futoshi Kurimoto
THTaiki Hakozaki
Taiki Hakozaki
MSMasahiro Seike
Masahiro Seike

12 July 2020 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
TTTakehiro Tozuka
Takehiro Tozuka
SKSatoru Kitazono
Satoru Kitazono
HSHiroaki Sakamoto
Hiroaki Sakamoto
HYHiroshi Yoshida
Hiroshi Yoshida
YAYoshiaki Amino
Yoshiaki Amino
MNMakoto Nishio
Makoto Nishio
Background: The efficacy of anti‐programmed cell death‐1/ligand 1 antibody monotherapy (anti‐PD‐1/PD‐L1 monotherapy) in patients with active brain metastases (BMs) is not established. Here, we aimed to evaluate the efficacy of anti‐PD‐1/PD‐L1 monotherapy in non‐small cell lung cancer (NSCLC) patients with active BMs.Methods: This retrospective study included NSCLC patients treated with second‐line or later‐line anti‐PD‐1/PD‐L1 monotherapy between December 2015 and August 2019. Patients were classified into those with or without active BMs, including symptomatic BMs requiring systemic steroids and untreated BMs. The progression‐free survival (PFS) and overall survival (OS) of the patients with and without active BMs were compared. Intracranial and extracranial tumor responses were evaluated in patients with active BMs.Results: We analyzed 197 patients who had received anti‐PD‐1/PD‐L1 monotherapy. Among them, 24 had active BMs. Among those without active BMs, 145 had no BMs and 28 had treated asymptomatic BMs. The PFS and OS of patients with active BMs were significantly shorter than those of patients without active BMs (1.3 vs. 2.7 months; P < 0.001, and 4.5 vs. 16.3 months; P = 0.001 respectively). For patients with active BMs, the intracranial and extracranial response rates were 13.3% and 26.7%, respectively. On multivariate analysis, active BMs, poor performance status (PS), and EGFR/ALK positivity were significant factors associated with shorter PFS. Active BMs and poor PS were significant factors associated with shorter OS.Conclusions: This study suggested that anti‐PD‐1/PD‐L1 monotherapy was not effective for NSCLC patients with active BMs. Further studies on immunotherapy are needed for patients with active BMs.Key points: Significant findings of the study: The present study showed that anti‐PD‐1/PD‐L1 antibody monotherapy was not effective for non‐small cell lung cancer patients with active brain metastases. Intracranial and extracranial response rates were 13.3% and 26.7%, respectively.What this study adds: Further studies on immunotherapy are needed for patients with active BMs.

11 September 2023 in Cancer Medicine
Verified
Journal Article
Open access
TTTakehiro Tozuka
Takehiro Tozuka
RNRintaro Noro
Rintaro Noro
AMAkihiko Miyanaga
Akihiko Miyanaga
SNShinji Nakamichi
Shinji Nakamichi
STSusumu Takeuchi
Susumu Takeuchi
MSMasahiro Seike
Masahiro Seike
Background: The epidermal growth factor receptor (EGFR) mutation is a risk factor associated with brain metastases (BMs) in patients with non‐small cell lung cancer (NSCLC). This study aimed to evaluate the impact of osimertinib early dose reduction on BM worsening.Methods: We retrospectively analyzed EGFR‐mutant NSCLC patients treated with osimertinib as first‐line treatment between August 2018 and October 2021. To evaluate the impact of osimertinib early dose reduction, we performed a landmark analysis of patients who achieved disease control at 4 months. Patients were divided into two groups according to whether the osimertinib dose was reduced or not, within 4 months after the start of treatment. We evaluated the time to BMs onset or progression, progression‐free survival, and overall survival.Results: In total, 62 NSCLC patients with EGFR mutations were analyzed. Thirteen patients experienced early dose reduction of osimertinib treatment. Seven patients received osimertinib 40 mg daily, and six received 80 mg every other day. The most common reason for dose reduction was gastrointestinal toxicity (n = 4), followed by skin rashes (n = 3). The time to BMs onset or progression was significantly shorter in patients who experienced early dose reduction than in those who continued regular treatment (Hazard ratio 4.47, 95% confidence interval, 1.52–13.11). The 1‐year cumulative incidence of BM onset or progression was 23.1% in the reduced‐dose group and 5.0% in the standard dose group. The risk of worsening BMs with early dose reduction of osimertinib treatment was higher in patients who had BMs before treatment and in younger patients.Conclusion: Early dose reduction of osimertinib was a risk factor for the worsening of BMs. A higher risk was associated with younger patients and those presenting BMs before treatment.

1 June 2025 in ESMO Open
Verified
Journal Article
Open access
KTK. Takagi
K. Takagi
GSG. Saito
G. Saito
HTH. Tanaka
H. Tanaka
SKS. Kubo
S. Kubo
TSTakehito Shukuya
Takehito Shukuya
TST. Suzuki
T. Suzuki
The REMORA trial demonstrated efficacy and safety of lenvatinib in patients previously treated for advanced thymic carcinoma. However, more data regarding its use in clinical practice are required. This multicenter retrospective study included consecutive patients with advanced thymic carcinoma who began lenvatinib treatment between 23 March 2021 and 31 October 2022. The primary outcome was the objective response rate in the previously treated group, with threshold and expected values based on the results of the REMORA trial and trials of other key drugs. Subgroup analyses were carried out based on REMORA trial eligibility criteria or age. Eighty-seven patients were enrolled in the previously treated group [median age, 64 years (range 38-79 years); 56 (64%) males]. Most patients [82 (94%)] had a performance status of 0 or 1; 51 (59%) met the trial eligibility criteria. The objective response rate and the disease control rate were 30% [90% confidence interval (CI) 21.3% to 39.1%] and 93% (95% CI 84.6% to 97.2%), respectively. The median progression-free survival, time to treatment failure, and overall survival were 10.2 months (95% CI 7.0-13.2 months), 11.6 months (95% CI 6.9-17.0 months), and not reached (NR; 95% CI 18.3 months-NR), respectively. Seventy-three patients (84%) required dose reduction owing to adverse events, including hypertension (22%), proteinuria (20%), and palmar-plantar erythrodysesthesia syndrome (16%). Twenty patients (23%) discontinued lenvatinib due to adverse events, including anorexia (6%), left ventricular systolic dysfunction (2%), and fatigue or malaise (2%). Two patients (2%) died of adverse events. Trial-eligible patients had significantly longer progression-free survival than that in trial-ineligible patients (14.7 months versus 7.7 months; P = 0.03). The incidence of adverse events was higher in older patients. The primary endpoint was unmet; however, lenvatinib demonstrated relatively favorable efficacy and safety in patients with previously treated thymic carcinoma, even in real-world clinical practice involving diverse populations.

1 September 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
TSTeppei Sugano
Teppei Sugano
MSMasahiro Seike
Masahiro Seike
RNRintaro Noro
Rintaro Noro
SKSyota Kaburaki
Syota Kaburaki
TTTakehiro Tozuka
Takehiro Tozuka
AGAkihiko Gemma
Akihiko Gemma
A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab Teppei Sugano,1 Masahiro Seike,1 Rintaro Noro,1 Syota Kaburaki,1 Takehiro Tozuka,1 Akihiko Takahashi,1 Natsuki Takano,1 Toru Tanaka,1 Takeru Kashiwada,1 Susumu Takeuchi,1 Yuji Minegishi,1 Yoshinobu Saito,1 Kaoru Kubota,1 Yasuhiro Terasaki,2 Akihiko Gemma1 1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan; 2Department of Analytic Human Pathology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan We herein describe the case of a 67-year-old woman with advanced lung adenocarcinoma who developed interstitial lung disease (ILD) with alveolar hemorrhage induced by pembrolizumab. She received four courses of pembrolizumab therapy and achieved a partial response. She had no respiratory symptoms; however, chest radiography and computed tomography (CT) revealed ground-glass opacities (GGOs) and crazy-paving pattern. Based on findings of bloody bronchoalveolar lavage fluid and transbronchial lung biopsy samples, pembrolizumab-induced ILD with alveolar hemorrhage was diagnosed. Corticosteroid therapy rapidly improved alveolar hemorrhage and regressed GGOs on CT scan. This is the first report on ILD with alveolar hemorrhage induced by pembrolizumab. Keywords: pembrolizumab, PD-1, pneumonitis, alveolar hemorrhage